Semaglutide, more commonly known as Ozempic, can do more than help with weight loss. A new clinical trial shows it helps ...

Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building its positions in peripheral artery disease (PAD) and with an oral formulation, based ...

Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...

CHICAGO — Semaglutide, a glucagon-like peptide (GLP-1) receptor agonist, has shown convincing benefits in yet another population: patients with peripheral arterial disease (PAD). In the STRIDE ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and type 2 diabetes in the first ...

Semaglutide associated with increased walking distance in patients with symptomatic peripheral artery disease and type 2 diabetes. (HealthDay News) — For patients with symptomatic peripheral ...

Perspective from Eugenia Gianos, MD CHICAGO — Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs. placebo, according to data from the ...

Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full results from STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly ...

Semaglutide may relieve peripheral arterial disease experienced by many patients with type 2 diabetes, a new Montreal study ...

Semaglutide 1 mg is the first medication ... approach to cardiometabolic diseases like type 2 diabetes and peripheral artery disease," said Michael Radin, MD, Executive Medical Director, Diabetes ...

Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...